RxDoctor Payments Data

Daniel Kellum, MD

Family Medicine · Schertz, TXNPI 1205820990

Payments from drug & device makers

$29,960in general payments, 2019–2025

Across 1,310 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$13K
  • AbbVie$3K
  • Amgen$2K
  • Novo Nordisk$1K
  • Amarin Pharma, Inc.$904
  • Lilly USA, LLC$867
  • plus $9K from 54 others

What the payments were for

  • Travel & lodging$3482%
  • Food & beverage$16,18895%
  • Education$4273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK39$12,969
AbbVie(2 entities)311$3,410
Amgen(2 entities)107$1,535
Novo Nordisk199$1,377
Amarin Pharma, Inc.70$904
Lilly USA, LLC52$867
Bayer31$606
Pfizer71$589
Astellas Pharma US Inc17$551
Regeneron2$508
Sanofi-aventis U.S. LLC28$446
Johnson & Johnson31$436
Boehringer Ingelheim21$364
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)23$348
AstraZeneca18$323
Zyla Life Sciences, Inc.36$299
Abbott18$268
Sumitomo Pharma America, Inc.11$255
Supernus Pharmaceuticals, Inc.13$231
Takeda Pharmaceuticals U.S.A., Inc.13$224
Almatica Pharma LLC10$202
Antares Pharma, Inc.19$192
Impel Pharmaceuticals Inc.13$178
Esperion Therapeutics, Inc.4$155
Biohaven Pharmaceutical Holding Company Ltd.9$150
Dexcom, Inc.8$150
Tris Pharma Inc6$145
Biodelivery Sciences International, Inc.5$143
Axsome Therapeutics, Inc.8$135
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$131
Merck8$125
Boston Scientific2$118
Corcept Therapeutics7$118
Intuitive Surgical1$111
Novartis8$108
Eisai Inc.6$92
Nevro Corp.3$67
Teva Pharmaceuticals USA, Inc.3$65
Caldera Medical, Inc1$64
Adlon Therapeutics L.p.4$60
Avanir Pharmaceuticals, Inc.3$54
Biohaven Pharmaceuticals, Inc.3$53
Harmony Biosciences LLC3$52
Abiomed1$51
Otsuka America Pharmaceutical, Inc.3$49
Shield Therapeutics Inc3$43
Ironwood Pharmaceuticals, Inc3$43
Neos Therapeutics, LP3$40
Assertio Therapeutics, Inc.10$39
Inspire Medical Systems, Inc.1$36
Actelion Pharmaceuticals US, Inc.1$34
QOL Medical, LLC3$34
Phathom Pharmaceuticals, Inc.2$34
Nestle Healthcare Nutrition Inc.2$33
Corium, LLC2$29
Optinose US, Inc.2$27
Kowa Pharmaceuticals America, Inc.2$26
Exeltis, USA Inc.1$24
Aerin Medical Inc.1$23
Lexicon Pharmaceuticals, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,960 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$152,637
Medicare patients
354
Services billed
3,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide139$185,296
OzempicSemaglutide119$149,498
EliquisApixaban84$83,376
TrulicityDulaglutide44$69,075
JardianceEmpagliflozin50$69,032
Soliqua 100-33Insulin Glargine/Lixisenatide50$64,031
LinzessLinaclotide34$45,211
FarxigaDapagliflozin Propanediol38$44,032
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$42,024
JanuviaSitagliptin Phosphate37$41,493
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$39,977
RybelsusSemaglutide17$37,269
TradjentaLinagliptin41$30,729
EntrestoSacubitril/Valsartan18$27,867
XareltoRivaroxaban22$23,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$867$254,371183 claims
Novo NordiskOzempic, Rybelsus$1,377$186,767136 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Synjardy Xr$364$125,425114 claims
PfizerEliquis$589$83,37684 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$323$70,28177 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$446$64,03150 claims
MerckJanuvia, Janumet$125$63,33066 claims
AbbVieLinzess$3,410$45,21134 claims
GSKTrelegy Ellipta$12,969$42,02434 claims
NovartisEntresto$108$27,86718 claims
Johnson & JohnsonXarelto$436$23,18822 claims
Astellas Pharma US IncMyrbetriq$551$16,06416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Schertz

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →